Yervoy - Drug Monograph

Introduction

Yervoy (ipilimumab) is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and is a foundational immune checkpoint inhibitor in oncology. It is approved for the treatment of unresectable or metastatic melanoma, adjuvant therapy of melanoma, and in combination with nivolumab for several malignancies including renal cell carcinoma, microsatellite instability–high/mismatch repair–deficient colorectal cancer, hepatocellular carcinoma, non–small cell lung cancer, and malignant pleural mesothelioma. Its clinical relevance lies in producing durable, long-term survival benefit in a subset of patients, but it is also associated with distinctive and sometimes severe immune-related adverse events (irAEs) that require prompt recognition and management.

Drug Class and Overview

• Class: IgG1 kappa fully human monoclonal antibody; immune checkpoint inhibitor (anti–CTLA-4).
• Related agents: Tremelimumab (another anti–CTLA-4 antibody, less widely used). Ipilimumab is often used in combination with anti–PD-1 agents (e.g., nivolumab) or anti–PD-L1 agents, which act on a complementary inhibitory pathway.
• Distinguishing features: Compared with PD-1/PD-L1 inhibitors, ipilimumab monotherapy is associated with a higher incidence of immune-related adverse events, particularly colitis, hypophysitis, and dermatitis. Combination ipilimumab plus nivolumab produces higher response rates and deeper responses than either agent alone, at the cost of substantially increased toxicity.

Mechanism of Action

CTLA-4 is an inhibitory receptor expressed on activated T lymphocytes that competes with CD28 for binding to the B7 costimulatory ligands (B7-1/CD80 and B7-2/CD86) on antigen-presenting cells. CTLA-4 engagement downregulates T-cell activation and is a physiologic brake on the immune response. Ipilimumab binds CTLA-4 with high affinity, blocking the interaction with B7 ligands and thereby removing the inhibitory signal. The net effect is enhanced T-cell priming, proliferation, and antitumor activity, including the expansion of tumor-reactive effector T cells and possibly depletion of regulatory T cells in the tumor microenvironment.

Indications

• Unresectable or metastatic melanoma (as monotherapy or in combination with nivolumab).
• Adjuvant treatment of melanoma in patients with pathologic involvement of regional lymph nodes who have undergone complete resection, including lymphadenectomy (as monotherapy).
• Intermediate- or poor-risk advanced renal cell carcinoma, in combination with nivolumab (first-line).
• Microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab.
• Hepatocellular carcinoma, in combination with nivolumab, in patients previously treated with sorafenib (per current FDA label).
• Metastatic or recurrent non–small cell lung cancer expressing PD-L1 (≥1%), in combination with nivolumab; also in combination with nivolumab and platinum-based chemotherapy regardless of PD-L1 expression (per current label).
• Unresectable malignant pleural mesothelioma, in combination with nivolumab (first-line).

Dosage and Administration

• Melanoma (unresectable/metastatic) monotherapy: 3 mg/kg IV over 90 minutes every 3 weeks for a maximum of 4 doses.
• Melanoma (adjuvant) monotherapy: 10 mg/kg IV over 90 minutes every 3 weeks for 4 doses, then every 12 weeks for up to 3 years (per FDA label).
• Combination with nivolumab (melanoma, RCC, CRC, HCC, NSCLC, mesothelioma): 1 mg/kg IV over 30 minutes every 6 weeks (some regimens use 3 mg/kg every 3 weeks for limited induction, depending on indication; refer to current FDA label and indication-specific protocols).
• Renal/hepatic adjustment: No formal renal or hepatic dose adjustment is recommended; monoclonal antibodies are not renally excreted and are catabolized like endogenous IgG. Use with caution in patients with severe organ dysfunction because of limited data.
• Pediatric: Safety and effectiveness in patients younger than 12 years have not been established for most indications; some pediatric labeling exists for certain combinations (refer to current label).
• Geriatric: No overall differences in safety/efficacy have been consistently reported, but older patients may have reduced tolerance for irAEs.
• Pregnancy/Lactation: Contraindicated in pregnancy based on mechanism (immune activation may harm the fetus). Effective contraception is recommended during treatment and for several months after the last dose. Breastfeeding is not recommended during therapy and for at least 3 months after the last dose.

Pharmacokinetics

• Absorption: Administered intravenously; bioavailability is 100% by definition.
• Distribution: Distributes primarily within the vascular compartment; steady-state volume of distribution is approximately 7–8 L.
• Metabolism: Catabolized via reticuloendothelial proteolytic degradation to small peptides and amino acids, similar to endogenous IgG. No cytochrome P450–mediated metabolism and no renal or hepatic excretion of intact drug.
• Elimination: Clearance is approximately 15–16 mL/h; minimal renal elimination.
• Half-life: Terminal elimination half-life is approximately 15 days (range ~12–21 days), supporting intermittent dosing every 2–3 weeks.

Contraindications

• Known severe hypersensitivity to ipilimumab or any component of the formulation.
• Active, life-threatening autoimmune disease for which additional immune activation would be hazardous (relative; refer to current label and guidelines).

Warnings and Precautions

• Severe and fatal immune-related adverse events can occur in any organ system. The most clinically important include:
• Immune-mediated colitis (can progress to perforation; high-risk with ipilimumab).
• Immune-mediated hepatitis (transaminitis, fulminant hepatic failure).
• Immune-mediated pneumonitis.
• Immune-mediated endocrinopathies: hypophysitis (particularly with ipilimumab), thyroid dysfunction, adrenal insufficiency, type 1 diabetes mellitus.
• Immune-mediated nephritis and renal dysfunction.
• Immune-mediated dermatitis, including severe rash, Stevens-Johnson syndrome, and toxic epidermal necrolysis (rare).
• Immune-mediated neurologic syndromes (myasthenia gravis, Guillain-Barré–like syndrome, encephalitis).
• Immune-mediated myocarditis (especially with combination regimens).
• Infusion-related reactions: Can occur; premedication is generally not required but standard emergency preparedness is necessary.
• Allogeneic hematopoietic stem cell transplant: Severe and fatal complications, including hyperacute graft-versus-host disease, have been reported in patients who received immune checkpoint inhibitors before or after transplant.
• Withhold/discontinue rules: Treatment must be held for moderate irAEs and permanently discontinued for severe, life-threatening, or recurrent events; high-dose corticosteroids (prednisone 1–2 mg/kg/day or equivalent) are the cornerstone of management, with escalation to other immunosuppressants (e.g., infliximab for steroid-refractory colitis, mycophenolate for hepatitis) when needed.

Drug Interactions

• No clinically significant pharmacokinetic interactions via CYP enzymes or renal transporters, because ipilimumab is a monoclonal antibody.
• Pharmacodynamic interactions:
• Systemic corticosteroids and other immunosuppressants given at immunosuppressive doses at the time of initiation may blunt the antitumor effect; however, corticosteroids used to manage irAEs after onset do not appear to abolish clinical benefit in most analyses.
• Other immunosuppressants (e.g., TNF-α inhibitors such as infliximab) used to treat steroid-refractory colitis do not appear to worsen tumor outcomes in available data, but should be used judiciously.
• Live vaccines: Concurrent use is contraindicated because of the risk of vaccine-induced infection in an immune-activated host; inactivated vaccines are acceptable but may produce diminished responses.
• Combination with other immune checkpoint inhibitors (e.g., nivolumab) markedly increases the incidence and severity of irAEs.

Adverse Effects

• Very common (≥20%): Fatigue, diarrhea, rash/pruritus, nausea, vomiting, decreased appetite, abdominal pain, pyrexia, headache, and infusion-related reactions.
• Common (10–20%): Immune-mediated endocrinopathies (thyroiditis, hypophysitis), transaminitis, colitis, arthralgia, cough, dyspnea.
• Serious/rare but clinically important:
• Severe colitis with perforation.
• Fulminant hepatitis.
• Hypophysitis with adrenal crisis.
• Pneumonitis.
• Myocarditis (especially with combination regimens).
• Severe neurologic syndromes.
• Stevens-Johnson syndrome / toxic epidermal necrolysis.
• Hemophagocytic lymphohistiocytosis.
• Laboratory abnormalities: Anemia, lymphopenia, neutropenia, thrombocytopenia, hyponatremia, hyperglycemia, elevated AST/ALT, elevated lipase/amylase, elevated creatinine.

Monitoring Parameters

• Baseline: Comprehensive metabolic panel (including AST, ALT, bilirubin, creatinine), complete blood count, thyroid function tests (TSH, free T4), morning cortisol or ACTH stimulation if clinically indicated, hepatitis B/C and HIV serologies per institutional protocol, pregnancy test when applicable, chest imaging, and assessment of performance status and autoimmune history.
• Before each dose: Symptom-directed history and physical examination; review bowel habits, skin, respiratory status, neurologic status, and endocrine symptoms.
• Routine labs: CBC, CMP, lipase/amylase, and TSH every cycle (commonly every 3 weeks during induction).
• Imaging: Tumor response assessment every 8–12 weeks using immune-related response criteria (irRECIST) or RECIST 1.1.
• Endocrine follow-up: Lifelong monitoring for hypophysitis, adrenal insufficiency, and thyroid dysfunction is recommended because some endocrinopathies are irreversible and require permanent hormone replacement.

Patient Education

• Report any new or worsening symptoms immediately, especially diarrhea, abdominal pain, blood in stool, jaundice, severe fatigue, persistent headache, visual changes, shortness of breath, cough, rash, or unusual weakness.
• Carry a wallet card or medical alert indicating treatment with an immune checkpoint inhibitor, in case emergency care is needed.
• Do not receive live vaccines during treatment; consult your oncology team before any vaccination.
• Use effective contraception during treatment and for several months after the last dose; do not breastfeed during therapy.
• Do not start new medications, supplements, or herbal products without discussing them with your oncology team.
• Understand that immune-related side effects can occur at any time during treatment and even after discontinuation; early reporting improves outcomes.
• Adhere to scheduled laboratory monitoring and clinic visits even if feeling well.

Clinical Pearls

• Ipilimumab is the prototypical anti–CTLA-4 agent; its toxicity profile (especially colitis and hypophysitis) is distinct from that of anti–PD-1/PD-L1 agents, and combination therapy amplifies both efficacy and toxicity.
• Immune-related adverse events are managed with a standardized stepwise approach: withhold for moderate events, permanently discontinue for severe events, and initiate high-dose corticosteroids early when indicated.
• Hypophysitis is a signature toxicity of ipilimumab; always evaluate morning cortisol and consider ACTH stimulation in patients with fatigue, headache, or hyponatremia, because adrenal crisis can be life-threatening.
• Unlike chemotherapy, response to ipilimumab can be delayed and may even be preceded by apparent radiographic progression ("pseudoprogression"); confirm progression with repeat imaging and clinical assessment before discontinuing therapy.
• Pharmacokinetic drug–drug interactions are minimal because ipilimumab is a non-glycosylated IgG1 antibody cleared by proteolysis; the clinically relevant interactions are pharmacodynamic (with other immunosuppressants and live vaccines).
• Durable, long-term remission is achievable in a subset of patients with metastatic melanoma, which is a hallmark of CTLA-4 blockade and a key rationale for its continued use in combination regimens.

References

1. Bristol-Myers Squibb. Yervoy (ipilimumab) Prescribing Information. U.S. Food and Drug Administration. Current label.
2. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Hepatobiliary Cancers, and Colon Cancer (current versions).
3. European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Cutaneous Melanoma, Renal Cell Carcinoma, and Metastatic Colorectal Cancer (current versions).
4. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology.
5. Goodman & Gilman's The Pharmacological Basis of Therapeutics. Chapter on Monoclonal Antibodies and Immune Checkpoint Inhibitors (current edition).
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. Section on Cancer Immunotherapy (current edition).
7. Lexicomp Online. Ipilimumab Drug Monograph. Wolters Kluwer Clinical Drug Information.
8. Micromedex (IBM Watson Health). Ipilimumab Drug Summary.
9. Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. New England Journal of Medicine.
10. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma (CheckMate 067). New England Journal of Medicine.
11. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (CheckMate 214). New England Journal of Medicine.
12. Baas P, Scherpereel A, Nowak AK, et al. First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743). The Lancet.